1 not yet recruiting, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow INCA33890: new trials by email Literature Review of INCA33890 trials Research Report on INCA33890
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial Comparing an Antibody (INCA33890) Versus Pembrolizumab for Squamous Cell Carcinoma of the Head and Neck. INCA33890, Pembrolizumab - Head and Neck Cancer Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Groupe Oncologie Radiotherapie Tete et Cou | 78 | 2027-02-01 | 2026-10-22 |
| A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy INCA33890 - CRC (Colorectal Cancer) | Phase 2 | Recruiting | Incyte Corporation | 40 | 2026-12-14 | 2026-11-17 |
Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Neoplasm, Residual (1)
Groupe Oncologie Radiotherapie Tete et Cou (1) · Incyte Corporation (1)
Puerto Rico (1) · United States (1)